Abstract
A new series of 3',4'-bis(3,4,5-trimethoxyphenyl)-4'H-spiro[indene-2,5'-isoxazol]-1(3H)-one derivatives was designed and synthesized. The cytotoxic effects of the synthesized compounds were evaluated on several different human cancer cells. Among them, compound 9e displayed the most potent in vitro antiproliferative activity with IC50 values of 0.07±0.01 µM on T47D cells. Another potent derivative 9h displayed an IC50 value of 0.12±0.07 µM against T47D cells, comparable to that of the positive controls (Colchicine Cisplatin Vincristine Vinblastine Doxorubicin Celecoxib). The structure-activity relationships were discussed and both anti-tubulin and COX-2 inhibitory effects were proposed for the developed compounds.
Keywords: Antitubulin, COX-2 inhibitor, 1, 3-dipolar cycloaddition, hybrid compounds, MTT assay, spiro-isoxazoline.
Letters in Drug Design & Discovery
Title:Design, Synthesis and in vitro Cytotoxicity Evaluation of New 3',4'-bis (3,4,5-trisubstituted)-4'H-spiro[indene-2,5'-isoxazol]-1(3H)-one Derivatives as Promising Anticancer Agents
Volume: 11 Issue: 10
Author(s): Hoda Abolhasani, Afshin Zarghi, Ahmad Abolhasani, Maryam Hamzeh-Mivehroud, Nasrin Bargahi, Behrouz Notash, Javid Shahbazi Mojarrad and Siavoush Dastmalchi
Affiliation:
Keywords: Antitubulin, COX-2 inhibitor, 1, 3-dipolar cycloaddition, hybrid compounds, MTT assay, spiro-isoxazoline.
Abstract: A new series of 3',4'-bis(3,4,5-trimethoxyphenyl)-4'H-spiro[indene-2,5'-isoxazol]-1(3H)-one derivatives was designed and synthesized. The cytotoxic effects of the synthesized compounds were evaluated on several different human cancer cells. Among them, compound 9e displayed the most potent in vitro antiproliferative activity with IC50 values of 0.07±0.01 µM on T47D cells. Another potent derivative 9h displayed an IC50 value of 0.12±0.07 µM against T47D cells, comparable to that of the positive controls (Colchicine Cisplatin Vincristine Vinblastine Doxorubicin Celecoxib). The structure-activity relationships were discussed and both anti-tubulin and COX-2 inhibitory effects were proposed for the developed compounds.
Export Options
About this article
Cite this article as:
Abolhasani Hoda, Zarghi Afshin, Abolhasani Ahmad, Hamzeh-Mivehroud Maryam, Bargahi Nasrin, Notash Behrouz, Mojarrad Shahbazi Javid and Dastmalchi Siavoush, Design, Synthesis and in vitro Cytotoxicity Evaluation of New 3',4'-bis (3,4,5-trisubstituted)-4'H-spiro[indene-2,5'-isoxazol]-1(3H)-one Derivatives as Promising Anticancer Agents, Letters in Drug Design & Discovery 2014; 11 (10) . https://dx.doi.org/10.2174/1570180811666140704172442
DOI https://dx.doi.org/10.2174/1570180811666140704172442 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CD147/EMMPRIN and CD44 are Potential Therapeutic Targets for Metastatic Prostate Cancer
Current Cancer Drug Targets HR-MAS NMR Spectroscopy: A Practical Guide for Natural Samples
Current Organic Chemistry Anti-Tuberculosis Drug Induced Hepatotoxicity and Genetic Polymorphisms in Drug-metabolizing Genes
Current Pharmacogenomics Recent Advances in Receptor-Targeted Fluorescent Probes for In Vivo Cancer Imaging
Current Medicinal Chemistry Design, Synthesis and Biological Evaluation of Quinoxalin-2(1H)-one Derivatives as EGFR Tyrosine Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Free Radicals and Antioxidants: How to Reestablish Redox Homeostasis in Chronic Diseases?
Current Medicinal Chemistry Pharmacological Activation of p53 in Cancer Cells
Current Pharmaceutical Design Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer
Current Gene Therapy A Proteomic Approach To Porcine Saliva
Current Protein & Peptide Science Development of Ribonucleotide Reductase Inhibitors: A Review on Structure Activity Relationships
Mini-Reviews in Medicinal Chemistry Molecular-Targeted and Cell-Based Therapies for Sjogren’s Syndrome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression
Current Molecular Medicine Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Meet Our Editorial Board Member
Mini-Reviews in Medicinal Chemistry Allelic Imbalances of the egfr Gene as Key Events in Breast Cancer Progression – the Concept of Committed Progenitor Cells
Current Cancer Drug Targets Fluorescent Cisplatin Analogues and Cytotoxic Activity
Current Medicinal Chemistry Image Fusion of Diagnostic Ultrasound with Other Modalities
Current Medical Imaging Paving Roads for New Drugs in Oncology
Recent Patents on Anti-Cancer Drug Discovery Development of WT1 Peptide Cancer Vaccine Against Hematopoietic Malignancies and Solid Cancers
Current Medicinal Chemistry Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
Current Cancer Drug Targets